Hengrui's Obesity Drug Rivals Zepbound in Late-Stage China Trial
Chinese patients taking the drug from Hengrui and Kailera Therapeutics lost up to 17.7% of their weight on average, the companies said in a statement this week. When adjusted for the placebo group, the drop in weight came in at 16.3% — a reduction comparable to what Eli Lilly & Co.'s Zepbound once showed in its China trial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
China EV brands Zeekr, Neta inflated car sales to hit targets
STORY: Chinese electric vehicle brands Zeekr and Neta inflated sales to hit aggressive targets. That's according to documents reviewed by Reuters and interviews with dealers and buyers. Documents from recent years show both companies arranged for cars to be insured before they were sold to buyers. This enabled them to book sales early under Chinese industry car registration practices, so they could hit monthly and quarterly targets, sources said. Switch Auto Insurance and Save Today! Great Rates and Award-Winning Service Affordable Auto Insurance, Customized for You The Insurance Savings You Expect Documents show Neta used this method for over 64,000 cars - more than half of vehicles sold from January 2023 to March 2024. Meanwhile, premium EV brand Zeekr used the same method to book early sales in late 2024, Reuters interviewees said. Vehicles booked as sold before reaching a buyer are called "zero-mileage used cars" in the Chinese auto industry. The practice has emerged out of cutthroat competition for sales in the world's largest auto market. The industry faces a moment of reckoning, with state media calling out the zero-mileage car practice. Meanwhile, China's cabinet has pledged to regulate "irrational" competition.
Yahoo
an hour ago
- Yahoo
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug
Key Takeaways Sarepta Therapeutics rejected the Food and Drug Administration's call to stop shipments of its muscular dystrophy drug. The FDA request came after a third patient in a Phase 1 study died while taking a similar treatment. Shares of the biopharma firm slid Monday, extending last week's Therapeutics (SRPT) shares continued to slide Monday after the biopharmaceutical firm refused a Food and Drug Administration (FDA) request to stop distributing its Elevidys treatment for muscular dystrophy. The FDA called for the halt after a third patient suffering from a form of muscular dystrophy taking a similar gene therapy to Elevidys in a Phase 1 study died of liver failure, possibly related to the drug. The news of the patient death sent shares of Sarepta plunging Friday. Elevidys has already been approved to treat both ambulatory and non-ambulatory patients with Duchenne muscular dystrophy. Sarepta voluntarily stopped shipments for non-ambulatory patients last month following a second death during the study to gauge the efficacy of the drug for Limb-Girdle muscular dystrophy. The company noted the third patient who died suffered from non-ambulant Limb-Girdle muscular dystrophy. However, Sarepta said that because its comprehensive scientific interpretation of the data 'shows no new or changed safety signals in the ambulant patient population, we will continue to ship ELEVIDYS to the ambulant population.' Sarepta said it's looking to 'continued discussions and sharing of information with FDA in order to advance our shared purpose of protecting patient safety and informed access to care." Shares of Sarepta were down about 3% in recent trading. They've lost nearly 90% of their value since the start of the year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Verge
an hour ago
- The Verge
Tesla's response to cratering sales? A deals blitz
With its sales in the crapper, Tesla is resorting to a slate of deals and incentives to get reinvigorate flagging customer interest in its lineup of electric vehicles. In recent days, the automaker has rolled out a series of discounts and financing incentives on all of its models, as it seeks to capitalize on what is likely to be its last best chance at a successful sales quarter. It's an understandable move, given how much of a drag this year has been for Tesla. The company recently reported a 14 percent drop in second quarter sales year over year. Tesla's sales in Europe have been in a serious slump with five straight consecutive months of decline. And in China, where the company is facing its fiercest competition from brands like BYD and Zeekr, second quarter sales were down 12 percent year over year — though there were some hints of a possible comeback in recent weeks. In the US, Tesla's response is the pull out all the stops. To start, every Tesla vehicle is eligible for the $7,500 federal EV tax credit until September 30th, when the incentive sunsets thanks to President Trump's budget bill. On top of that, Tesla is also offering one free month of Full Self-Driving (Supervised) driver assist feature, as well as a free trial of its Premium Connectivity package (one month for Model 3 and Y, and one year for Model S, X, and Cybertruck). And there's also a $1,000 discount for 'American heroes' like members of the military, teachers, and first responders. Moreover, all models except the Cybertruck are eligible for a free upgrade for a limited time. And the Model 3 and Cybertruck come with 0 percent APR financing with a purchase of the FSD package. And the Model 3 also comes with 18 months of free Supercharging for cash purchases. Meanwhile, Model Y buyers with 'excellent credit' and a 15 percent down payment can get 3.49 percent APR financing, down from 5.54 percent. Cybertruck buyers of a similar status can also get 0 percent APR, as well as a free 20-inch 'Cyber wheel' upgrade, which typically have a $3,500 value. And for anyone interested in the company's practically ancient Model S or X (though they did just get a mild refresh), Tesla is offering a free upgrade when you purchase the FSD feature. The third quarter is likely going to be a high water mark for Tesla, giving the expiring federal incentives and an expectation that EV prices will be going up across the board. Tesla has tried to juice sales by refreshing its models with new designs and a mild tech upgrade, but Elon Musk's polarizing persona has made it increasingly difficult for the company to climb out of its rut. And the newest model, the Cybertruck, is just a sales dud and arguably one of the biggest automotive flop in decades — no one wants it. Of course, Tesla could reverse its fortunes with the release of a new, more affordable EV — not just a cheaper Model 3 or Y. The company has been promising a cheaper model for years now, though Musk has said he's more interested in pushing robotaxis and humanoid robots than spending resources on a budget EV. The CEO recently teased an 'epic demo' of a new Tesla project by the end of the year. The company is expected to report another steep drop in profits in its Q2 earnings on Wednesday, July 23rd.
